ACOTIAMIDE MARKET

INTRODUCTIONACOTIAMIDE MARKET

Acotiamide is used to treat indigestion-related early satiety (feeling extremely full after only a few bites of food), upper abdominal pain, and bloating after meals. Acotiamide also reduced the hypomotility brought on by clonidine and postponed stomach emptying.

Atropine pretreatment totally reduced the postprandial gastroduodenal motility that acotiamide increased. Acotiamide's AChE inhibitory effect was both selective and reversible.

According to numerous studies, eating foods like onions, peppers, fried and fatty foods, alcohol, citrus fruits, and spicy foods might cause dyspeptic symptoms. Functional dyspepsia treatment can be challenging for medical professionals and patients.

Functional dyspepsia can manifest as stomach pain or burning after eating, as well as bloating, frequent belching, or nausea. a sensation of satiety after eating that comes on quickly. Occasionally, stomach pain may not be related to meals or it may be relieved by eating.

This medication appears to have an antagonistic impact on muscarinic M1, M2, and M3 receptors, decreasing the negative feedback mechanism by blocking muscarinic auto receptors that control acetylcholine production. It is beneficial in treating people with functional dyspepsia.

ACOTIAMIDE MARKET SIZE AND FORECAST

The Global ACOTIAMIDE market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

ACOTIAMIDE MARKETNEW PRODUCT LAUNCH

Zeria Pharmaceutical Co., Ltd. in Japan created the unique oral prokinetic medication acotiamide to treat patients with functional dyspepsia. In spite of any organic abnormalities present, FD is a functional gastrointestinal condition with upper abdominal symptoms such postprandial fullness, upper abdominal distension, and early satiety from the gastroduodenal area.

Postprandial distress syndrome (PDS) and epigastric pain syndrome are two additional categories for FD. International diagnostic standards describe the symptom's duration (Rome III criteria). The requirements must be met for the. Prior to diagnosis, onset should be at least six months old. To relieve abdominal symptoms brought on by hypomotility, acotiamide regulates upper gastrointestinal motility.

Numerous medications have been developed to increase muscular activity in order to alleviate the symptoms of hypomotility brought on by gastrointestinal problems, such as sluggish transit constipation and delayed gastric empting.

Acetylcholinesterase inhibitors or the activation of 5hydroxytryptamine receptors on cholinergic nerve endings in the enteric nervous system increase the release of acetylcholine (ACh) from motor neurons, which in turn promotes gastrointestinal propulsive motility. 

receptor agonists and other stomach prokinetic drugs like dopamine receptor antagonists have mostly been created as a result of these pharmacological studies. Dopamine receptor antagonists like domperidone, which cause extrapyramidal syndrome and raise plasma prolactin levels, are beneficial for treating gastroparesis or nausea.

ACOTIAMIDE MARKETCOMPANY PROFILE

• Globus Labs
• Fibovil Pharmaceuticals Private Limited
• Sanify Healthcare Private Limited
• Healing Pharma India Private Limited
• Corsantrum Technology

THIS ACOTIAMIDE MARKETREPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many ACOTIAMIDE are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global ACOTIAMIDE and key vendor selection criteria
3. Where is the ACOTIAMIDE manufactured? What is the average margin per unit?
4. Market share of Global ACOTIAMIDE market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global ACOTIAMIDE in-house
6. key predictions for next 5 years in Global ACOTIAMIDE market
7. Average B-2-B ACOTIAMIDE market price in all segments
8. Latest trends in ACOTIAMIDE market, by every market segment
9. The market size (both volume and value) of the ACOTIAMIDE market in 2024-2030 and every year in between?
10. Production breakup of ACOTIAMIDE market, by suppliers and their OEM relationship